In particular, in recent years, significant progress has been achieved with the success of chimeric antigen receptor (CAR) T cell therapy and bispecific antibodies, such as Blinatumomab, for hematological malignancies, leading to the approval of a number of CD19-targeted therapy products [31,32] by the US Food and Drug Administration (FDA). The gene discussed is CD19; the disease is hematologic disorder.